Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
The Year Ahead: What to Expect in 2017
“New funding, FDA clearances, and more
As we consider what 2017 has in store for the biomedical community, we’re pleased to kick off the year with the recent FDA clearance of our ARIES® GBS Assay for Streptococcus agalactiae (more commonly known as Group B Streptococcus). By most estimates, between 12 percent and 27 percent of pregnant women harbor GBS and can pass it on to their children during delivery. Here in the U.S., this pathogen is the leading cause of meningitis and sepsis in the first week of a newborn’s life…”
At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.
First Coast Infectious Disease/Clinical Microbiology Symposium
St. Augustine, FL
ASM Biothreats: Research, Response & Policy Meeting
NCASM Spring Meeting
San Francisco, CA
FAH Public Policy Conference & Business Expo
SCACM Spring Meeting